Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC

Clinical trial NCT07158489 · RECRUITING

Trial details

NCT number: NCT07158489
Sponsor: Swiss Cancer Institute
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

NSCLC NSCLC (Advanced Non-small Cell Lung Cancer)

Start date: 2026-09-01
Primary completion: 2028-07-01
Enrollment: 47

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.